^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PGR (Progesterone receptor)

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    1d
    The VEGF/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies. (PubMed, Gene)
    In addition, we highlight the importance of molecular stratification and biomarker-driven approaches to identify patients most likely to benefit from anti-angiogenic therapy. Overall, while VEGFR-targeted therapy alone has shown limited success, rational combination strategies and improved patient selection may significantly enhance its clinical utility in TNBC.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression
    2d
    Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. (PubMed, Oncol Rev)
    Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.
    Review • Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    2d
    CDK and Body Composition Study (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Montefiore Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • LEP (Leptin)
    2d
    Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Emory University | Trial completion date: Apr 2027 --> Feb 2028 | Trial primary completion date: Apr 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    Keytruda (pembrolizumab)
    3d
    HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov)
    P1, N=31, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    3d
    ER, PR, and HER2 triple positivity and triple negativity are associated with adverse prognostic significance in endometrial serous carcinoma. (PubMed, Virchows Arch)
    Stratification based on combined receptor status may facilitate more personalized treatment approaches and improve clinical outcomes in this aggressive malignancy. Further large-scale studies are needed to validate these findings and explore targeted therapeutic strategies for high-risk subgroups.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive
    3d
    Invasive Micropapillary Carcinoma of the Breast with an Encapsulated-Like Pattern: An Unreported Entity? (PubMed, Int J Surg Pathol)
    Two sentinel lymph nodes were negative. To our knowledge, invasive micropapillary carcinoma with an encapsulated pattern has not been previously reported.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    3d
    Associations Between Apparent Diffusion Coefficient Values and Histopathologic Prognostic Factors in Breast Cancer: A Retrospective Study. (PubMed, Int J Breast Cancer)
    Additionally, Grade I tumors had higher ADC values than Grade II and III tumors (p < 0.01), while no difference was observed between Grade II and III tumors (p = 0.61). Lower ADC values correlate with higher tumor grades and Ki-67 expression, suggesting their potential role as imaging biomarkers for assessing breast cancer aggressiveness.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    3d
    Effect of capsule invasion on recurrence and survival in axillary lymph node metastases of breast cancer. (PubMed, Rev Assoc Med Bras (1992))
    Although lymph node capsule invasion in breast cancer with axillary lymph node involvement does not significantly impact overall survival, it independently and significantly elevates the risk of recurrence, as demonstrated by multivariate analysis.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    3d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Recruiting, West German Study Group | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Orserdu (elacestrant)
    3d
    NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=782, Active, not recruiting, NRG Oncology | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    3d
    CLEE011AIC01: A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=175, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=550 --> 175
    Trial completion • Enrollment change • HEOR • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib)